Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

Annals of Oncology 2026

View at publisher

Authors: Roberto Contieri, Veronica Mollica, Shahrokh F. Shariat, Benjamin Pradere

DOI: 10.1016/j.annonc.2026.01.003

Cited by: 1

References: 3

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Immune responses and vaccinations Pediatric Urology and Nephrology Studies

References 3